Table 12.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1995 to 2004

Recipients with Lung Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 893 836 948 893 922 977 1,083 1,054 1,099 1,185
Tx with Antirejection Treatments 475 381 421 403 397 432 500 427 355 382
Antibodies Any in Category 9.5% 10.8% 11.6% 15.9% 16.1% 18.8% 11.4% 13.3% 16.1% 13.9%
Atgam/NRATG/NRATS 5.7% 7.3% 7.8% 10.9% 8.1% 7.4% 4.2% 3.0% 4.8% 4.2%
OKT3 4.2% 3.7% 4.3% 3.2% 3.0% 2.5% 1.4% 1.9% 0.8% 1.0%
Thymoglobulin 0.2% 0.0% 0.0% 0.7% 5.0% 5.8% 6.0% 4.9% 5.6% 6.8%
Zenapax 0.0% 0.0% 0.2% 2.2% 1.0% 3.0% 0.8% 5.2% 7.0% 1.8%
Simulect 0.0% 0.0% 0.0% 0.2% 0.8% 2.8% 0.6% 0.2% 0.6% 0.5%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.5% 0.6% 0.5%
Corticosteroids Any in Category 93.7% 90.0% 94.1% 91.6% 92.9% 88.2% 92.4% 94.8% 96.3% 93.7%
Steroids 93.7% 90.0% 94.1% 91.6% 92.9% 88.2% 92.4% 94.8% 96.3% 93.7%
Antimetabolites Any in Category 1.1% 5.0% 1.9% 0.7% 1.5% 1.2% 1.2% 0.2% 1.4% 0.5%
Cytoxan 0.0% 0.8% 0.5% 0.2% 0.8% 0.5% 0.2% 0.2% 0.6% 0.5%
Methotrexate 1.1% 4.2% 1.4% 0.5% 1.5% 0.7% 1.0% 0.0% 0.8% 0.0%


Source: OPTN/SRTR Data as of May 1, 2006.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.